In silico design of novel precision vaccine targeting sclerostin epitopes for osteoporosis prevention and treatment.

ABSTRACT:

Background

Osteoporosis has become an increasingly pressing global public health challenge. Monoclonal antibody romosozumab (ROMO), which targets sclerostin (SOST), a critical inhibitor of bone formation, demonstrates considerable therapeutic efficacy. However, its relatively high cost and potential cardiovascular risks may hinder broader clinical application. Current preventive measures remain inadequate.

Methods

This study presents a novel, cost-effective osteoporosis vaccine with dual preventive and therapeutic capabilities, derived from the high-affinity binding epitope of ROMO to SOST. ELISA screening determined that the SOST_131-163 region within loop3 domain serves as the primary epitope for ROMO, suggesting a role in skeletal regulation with minimal impact

SUBMITTER: Luo J 

PROVIDER: S-EPMC12702773 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature